NASDAQ:CRSP - Crispr Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Crispr Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $65.24 -0.79 (-1.20 %) (As of 12/13/2019 03:31 PM ET) Add Compare Today's Range$64.35Now: $65.24▼$67.3750-Day Range$39.47MA: $58.41▼$73.0952-Week Range$22.22Now: $65.24▼$74.00Volume631,537 shsAverage Volume1.65 million shsMarket Capitalization$3.60 billionP/E RatioN/ADividend YieldN/ABeta3.31 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRSP Previous Symbol CUSIPN/A CIK1674416 Webhttp://www.crisprtx.com/ Phone41-41-561-3277Debt Debt-to-Equity Ratio0.06 Current Ratio8.32 Quick Ratio8.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio100.37 P/E GrowthN/A Sales & Book Value Annual Sales$3.12 million Price / Sales1,154.25 Cash FlowN/A Price / Cash FlowN/A Book Value$7.56 per share Price / Book8.63Profitability EPS (Most Recent Fiscal Year)($3.44) Net Income$-164,980,000.00 Net Margins-5.30% Return on Equity-2.60% Return on Assets-2.05%Miscellaneous Employees188 Outstanding Shares55,200,000Market Cap$3.60 billion Next Earnings Date2/24/2020 (Estimated) OptionableOptionable Receive CRSP News and Ratings via Email Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CRSP Rates by TradingView Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions What is Crispr Therapeutics' stock symbol? Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP." How were Crispr Therapeutics' earnings last quarter? Crispr Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings results on Monday, October, 28th. The company reported $2.40 EPS for the quarter, topping the Zacks' consensus estimate of ($0.95) by $3.35. The business earned $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. View Crispr Therapeutics' Earnings History. When is Crispr Therapeutics' next earnings date? Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Crispr Therapeutics. What price target have analysts set for CRSP? 15 brokers have issued 12 month price objectives for Crispr Therapeutics' shares. Their forecasts range from $21.00 to $104.00. On average, they expect Crispr Therapeutics' stock price to reach $70.86 in the next twelve months. This suggests a possible upside of 8.6% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics. What is the consensus analysts' recommendation for Crispr Therapeutics? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics. What are Wall Street analysts saying about Crispr Therapeutics stock? Here are some recent quotes from research analysts about Crispr Therapeutics stock: 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (9/30/2019) 2. Needham & Company LLC analysts commented, "Crispr reported 1Q19 financial results yesterday and we spoke w/ mgmt for an update. The company announced last night that regulatory agencies in both the U.S. and Canada have cleared initiation of a Phase 1/2 trial of CTX-110, an allogeneic CAR-T cell therapy in development for CD-19 cancers. Mgmt reiterated guidance for trial initiation in 2Q19. 1/2 trials of CTX-001 continue to enroll pts, although infusion of first pt in latter trial is not expected until mid-2019. Mgmt still aspires to present data from the CTX-001 program at the ASH mtg in Dec 2019, depending on trial progress. Reiterate BUY. Progression of CRISPR-based allogeneic CAR-T program into the clinic later in 2Q19 represents important milestone for the company." (5/1/2019) 3. William Blair analysts commented, "CRISPR Therapeutics AG We are initiating coverage on CRISPR Perform rating and $39 fair value estimate. While we acknowledge the innovative nature of the CRISPR/Cas9 discovery and the ease of use and flexibility of the platform as a potential ex vivo and in vivo therapeutic modality, we view the most-progressed indications being targeted—beta-thalassemia and sickle cell with CTX001 in col- laboration with Vertex and allogeneic T-cell therapy for hematological malignancies (acute lymphocytic leukemia [ALL], non-Hodgkin lymphoma [NHL], and multiple myeloma [MM])—as hyper-competitive spaces where the company is behind the leaders in clinical development." (3/13/2019) Has Crispr Therapeutics been receiving favorable news coverage? Media stories about CRSP stock have been trending somewhat positive on Friday, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Crispr Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Crispr Therapeutics. Are investors shorting Crispr Therapeutics? Crispr Therapeutics saw a decrease in short interest in the month of November. As of November 29th, there was short interest totalling 3,620,000 shares, a decrease of 34.9% from the November 14th total of 5,560,000 shares. Based on an average trading volume of 914,900 shares, the short-interest ratio is currently 4.0 days. Currently, 10.6% of the shares of the stock are short sold. View Crispr Therapeutics' Current Options Chain. Who are some of Crispr Therapeutics' key competitors? Some companies that are related to Crispr Therapeutics include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO) and Iovance Biotherapeutics (IOVA). What other stocks do shareholders of Crispr Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), Micron Technology (MU), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Canopy Growth (CGC), Shopify (SHOP), Netflix (NFLX), Advanced Micro Devices (AMD) and Sangamo Therapeutics (SGMO). Who are Crispr Therapeutics' key executives? Crispr Therapeutics' management team includes the folowing people: Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)Dr. Samarth Kulkarni, CEO & Director (Age 40)Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)Dr. Tony W. Ho, Head of R&D and Exec. VPDr. N. Anthony Coles Jr., Sr. Advisor (Age 59) When did Crispr Therapeutics IPO? (CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Crispr Therapeutics' major shareholders? Crispr Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (7.75%), Nikko Asset Management Americas Inc. (5.08%), Orbimed Advisors LLC (0.94%), Global Thematic Partners LLC (0.63%), Millennium Management LLC (0.19%) and Essex Investment Management Co. LLC (0.14%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View Institutional Ownership Trends for Crispr Therapeutics. Which major investors are selling Crispr Therapeutics stock? CRSP stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Versant Venture Management LLC, Essex Investment Management Co. LLC, Patriot Financial Group Insurance Agency LLC, Clear Creek Financial Management LLC, Capital Investment Advisory Services LLC, Flagship Harbor Advisors LLC and Point72 Asset Management L.P.. Company insiders that have sold Crispr Therapeutics company stock in the last year include Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak and Samarth Kulkarni. View Insider Buying and Selling for Crispr Therapeutics. Which major investors are buying Crispr Therapeutics stock? CRSP stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Orbimed Advisors LLC, Millennium Management LLC, First Trust Advisors LP, SG Americas Securities LLC, Nvwm LLC, Janney Montgomery Scott LLC and Barclays PLC. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer and Vertex Pharmaceuticals (Europe. View Insider Buying and Selling for Crispr Therapeutics. How do I buy shares of Crispr Therapeutics? Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Crispr Therapeutics' stock price today? One share of CRSP stock can currently be purchased for approximately $65.24. How big of a company is Crispr Therapeutics? Crispr Therapeutics has a market capitalization of $3.60 billion and generates $3.12 million in revenue each year. The company earns $-164,980,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.View Additional Information About Crispr Therapeutics. What is Crispr Therapeutics' official website? The official website for Crispr Therapeutics is http://www.crisprtx.com/. How can I contact Crispr Therapeutics? Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected] MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 295 (Vote Outperform)Underperform Votes: 283 (Vote Underperform)Total Votes: 578MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: What is an Initial Coin Offering (ICO)?
